Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04878055 · ClinicalTrials.gov registry record · Phase 3
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
A Phase 3 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT04878055 is a Phase 3 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 287 participants.
The verdict
NCT04878055, a Phase 3 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
Interventions
- OTHER Placebo
- DRUG Reparixin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2021-02-14 |
| Est. Completion | 2021-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04878055
The ClinicalTrials.gov registry entry for NCT04878055 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04878055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04878055 about?
NCT04878055 is a clinical study titled "Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.". The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
What is the current status of trial NCT04878055?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2021-02-14. Estimated completion is 2021-10-31.
What interventions are being tested in trial NCT04878055?
The interventions under investigation include: Placebo (OTHER), Reparixin (DRUG).
Who is sponsoring clinical trial NCT04878055?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.